| Background | Alirocumab biosimilar is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9) , is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab biosimilar consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single Nlinked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab biosimilar has an approximate molecular weight of 146 kDa. |
Information sourced from Uniprot.org
